(Photo via Pexels https://www.pexels.com/photo/airport-bank-board-business-534216/)
Clinical-stage biotech company Cabaletta Bio Inc. announced that it had raised $74.8 million in an initial public offering Friday.
The University City-based company sold 6.8 million shares of common stock at $11 per share, according to a company statement. The pricing is below its target price of $14 to $16 per share listed in documents filed with the Securities and Exchange Commission, Philadelphia Business Journal reported.
Cabaletta, a University of Pennsylvania spinout, develops engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The announcement marks the city’s first life sciences IPO of 2019.
On Monday, Cabaletta (NASDAQ: CABA) was trading around $10 a share. The company said it expects its net proceeds from the offering to be about $66.2 million.
The technology was developed at Penn and resulted in the first commercially available CAR T cell products for the treatment of B cell cancers. The company was founded in 2017 by Dr. Michael Milone and Dr. Aimee Payne, who serve as co-chairs of Cabaletta’s Scientific Advisory Board, the company said. Dr. Steven Nichtberger also cofounded, and now serves as Cabaletta’s CEO.
This year, University City-based Spark Therapeutics (NASDAQ: ONCE) was the focus of what will be the largest exit ever within city limits for a venture-backed company, once it’s complete, after going public in 2015.
A cell and gene therapy development center is taking 680K square feet at KOP’s Discovery Labs
10 imagined futures: Philly’s tech community tells us what they envision for the next decade
Inside University City’s push to get those without four-year degrees into STEM careers
Success in life sciences begets more success: What Philly leaders say about the industry’s growth
Sign-up for daily news updates from Technical.ly Philadelphia